Note: Descriptions are shown in the official language in which they were submitted.
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
METHODS OF TREATING HEPATITIS
Cross-Reference to Related Applications
This application claims priority to U.S. Provisional Application No.
60/381,527
filed May 17, 2002, which is incorporated herein by reference in its entirety.
Statement as to Federally Sponsored Research
This invention was made with Government support under National Institutes of
Health Grant Nos. RO1-GM-44100, HL 58688, HL55330, HL60234, and AI42365. The
Government has certain rights in this invention.
Technical Field
This invention relates to the treatment of hepatitis.
Back rg ound
Carbon monoxide gas is poisonous in high concentrations. However, it is now
recognized as an important signaling molecule (Verma et al., Science 259:381-
384,
1993). It has also been suggested that carbon monoxide acts as a neuronal
messenger
molecule in the brain (Id.) and as a neuro-endocrine modulator in the
hypothalamus
(Pozzoli et al., Endocrinology 735:2314-2317, 1994). Like nitric oxide (NO),
carbon
monoxide is a smooth muscle relaxant (Utz et al., Biochem Pharmacol. 47:195-
201,
1991; Christodoulides et al., Circulation 97:2306-9, 1995) and inhibits
platelet
2o aggregation (Mansouri et al., Thromb Haemost. 48:286-8, 1982). Inhalation
of low
levels of carbon monoxide (CO) has been shown to have anti-inflammatory
effects in
some models.
Hepatitis is a disease characterized by inflammation of the liver. The
inflammation can be characterized by diffuse or patchy necrosis affecting
acini.
2s Causative agents of hepatitis include, for example, viruses, e.g., specific
hepatitis
viruses, e.g., hepatitis A, B, C, D, E, and G viruses; alcohol; and other
drugs (e.g.,
isoniazid, methyldopa, acetaminophen, amiodarone, and nitrofurantoin) (see The
Merck
Manual of Diagnosis and Therapy, 17'" Edition, Section 4, Chapter 42).
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Summary
The present invention is based, in part, on the discovery that administration
of
CO can protect against the development of hepatitis.
Accordingly, the present invention features a method of treating, preventing,
or
reducing the risk of, hepatitis in a patient. The method includes identifying
a patient
diagnosed as suffering from or at risk for hepatitis (e.g., a patient
diagnosed as suffering
from or at risk for hepatitis), and administering to the patient a
pharmaceutical
composition comprising an amount of carbon monoxide effective to treat
hepatitis in
the patient.
1o The pharmaceutical composition can be administered to the patient by any
method known in the art for administering gases and/or liquids to patients,
e.g., via
inhalation, insufflation, infusion, injection, and/or ingestion. In one
embodiment of the
present invention, the pharmaceutical composition is administered to the
patient by
inhalation. In another embodiment, the pharmaceutical composition is
administered to
is the patient orally. In still another embodiment, the pharmaceutical
composition is
administered directly to the abdominal cavity of the patient. In yet another
embodiment, the pharmaceutical composition is administered by an
extracorporeal
membrane gas exchange device or an artificial lung. In another embodiment, the
patient is an alcoholic.
2o The patient can be an animal, human or non-human. For example, the patient
can be any mammal, e.g., humans, other primates, pigs, rodents such as mice
and rats,
rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats. The
hepatitis
can be the result of, or a person may be considered at risk for hepatitis
because of, any
of a number of factors, e.g., infections, e.g., viral infections, e.g.,
infection with
25 hepatitis A, B, C, D, E and/or G virus; alcohol use (e.g., alcoholism);
drug use (e.g., one
or more drugs described herein, e.g., acetaminophen, anesthetics, anti-
tuberculous
drugs, antifungal agents, antidiabetic drugs, neuroleptic agents, and drugs
used to treat
HIV infection and AIDS); autoimmune conditions (e.g., autoimmune hepatitis);
and/or
surgical procedures. The pharmaceutical composition can be in any form, e.g.,
gaseous
30 or liquid form.
In another embodiment, the method further includes administering to the
patient
at least one of the following treatments: inducing HO-1 or ferritin in the
patient;
expressing recombinant HO-1 or ferritin in the patient; and administering a
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
pharmaceutical composition comprising HO-l, bilirubin, biliverdin, ferntin, or
apoferntin, iron, desferoxamine, or iron dextran to the patient. Also
contemplated is
use of CO and any of the above-listed agents in the preparation of a
medicament for
treatment or prevention of hepatitis.
In another embodiment, the hepatitis (or the risk for hepatitis) is not caused
by
surgery (e.g., abdominal or transplant surgery), bacterial endotoxin, septic
shock,
and/or systemic inflammation.
In another aspect, the invention features a method of treating or preventing
hepatitis in a patient, which includes identifying a patient suffering from or
at risk for
hepatitis (e.g., a patient diagnosed as suffering from or at risk for
hepatitis), providing a
vessel containing a pressurized gas comprising carbon monoxide gas, releasing
the
pressurized gas from the vessel to form an atmosphere comprising carbon
monoxide
gas, and exposing the patient to the atmosphere, wherein the amount of carbon
monoxide in the atmosphere is sufficient to treat hepatitis in the patient.
In still another aspect, the invention features a method of performing
abdominal
surgery, e.g., liver transplantation, on a patient, which includes identifying
a patient in
need of abdominal surgery, wherein hepatitis is a risk of the abdominal
surgery;
performing abdominal surgery on the patient, and before, during, or after the
performing step, causing the patient to inhale an amount of carbon monoxide
gas
2o sufficient to reduce the risk of hepatitis in the patient. Also
contemplated is use of CO
in the preparation of a medicament, e.g., a gaseous or liquid medicament, for
use in the
treatment or prevention of hepatitis.
The invention also features a method of treating hepatitis in a patient
suffering
from or at risk for hepatitis not caused by surgery and/or endotoxin, e.g.,
hepatitis
2s caused by any factor described herein other than surgery and/or endotoxin.
The method
includes identifying a patient suffering from or at risk for hepatitis not
caused by
surgery and/or endotoxin and administering to the patient a pharmaceutical
composition
comprising an amount of carbon monoxide effective to treat hepatitis in the
patient.
Also within the invention is a method of administering a hepatitis-inducing
drug
so (i.e., a hepatotoxic drug, e.g., isoniazid, methyldopa, acetaminophen,
amiodarone, or
nitrofurantoin) to a patient. The method includes administering the drug to
the patient,
and before, during, and/or after administering the drug, administering to the
patient a
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
pharmaceutical composition comprising carbon monoxide in an amount effective
to
treat hepatitis in the patient.
In another aspect, the invention provides a vessel comprising medical grade
compressed CO gas. The vessel can bear a label indicating that the gas can be
used to
treat hepatitis in a patient. Alternatively or in addition, the vessel can
bear a label
indicating that the gas can be administered to a patient in conjunction with
administration of a hepatitis-inducing drug (i.e., a hepatotoxic drug), e.g.,
acetaminophen. The CO gas can be in an admixture with nitrogen gas, with
nitric
oxide and nitrogen gas, or with an oxygen-containing gas. The CO gas can be
present
~o in the admixture at a concentration of at least about 0.025%, e.g., at
least about 0.05%,
0.10%, 0.50%, 1.0%, 2.0%, 10%, 50%, or 90%.
Also within the invention is the use of CO in the manufacture of a medicament
for treatment or prevention of hepatitis. The medicament can be used in a
method for
treating hepatitis in a patient suffering from or at risk for hepatitis in
accordance with
~s the methods described herein. The medicament can be in any form described
herein,
e.g., a liquid or gaseous CO composition.
Unless otherwise defined, all technical and scientific terms used herein have
the
same meaning as commonly understood by one of ordinary skill in the art to
which this
invention belongs. Suitable methods and materials are described below,
although
2o methods and materials similar or equivalent to those described herein can
be used in the
practice or testing of the present invention. All publications, patent
applications,
patents, and other references mentioned herein are incorporated by reference
in their
entirety. In case of conflict, the present specification, including
definitions, will
control. The materials, methods, and examples are illustrative only and not
intended to
25 be limiting.
The details of one or more embodiments of the invention are set forth in the
description below. Other features, objects, and advantages of the invention
will be
apparent from the description and the claims.
so BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a bar graph illustrating that induction of HO-1 protects mouse
hepatocytes from TNF-a/D-gal-induced cell death. CoPP = cobalt protoporphyrin;
4
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
ALT = serum alanine aminotransferase; TNF = tumor necrosis factor alpha.
Results
are the mean ~ SD
of 6-8 mice/group *p<0.005.
Fig. 2 is a bar graph illustrating that exogenous CO protects hepatocytes
against
s TNF-a - induced cell death in a cGMP/p38 pathway-independent and an NF-oB
activation-dependent manner. CO = carbon monoxide; Air = room air; TNF = tumor
necrosis factor alpha; BAY = BAY 11-7082 (inhibits NF-kB activation); IoB =
IxBa
(prevents NF-xB activation); ODQ = 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one
(a
selective guanylyl cyclase inhibitor); Lac-Z = pIEP-Lac-Z (adenoviral
control). Results
shown are the mean ~ SD of triplicate wells from four independent experiments
(*p<0.01).
Fig. 3 is a bar graph illustrating that exogenous CO protects human
hepatocytes
against TNF-a/Actinomycin-D (ActD) - induced cell death. CO = carbon monoxide;
Air = room air; TNF = TNF-alActD. Results are mean ~ SD of triplicate wells
from 3
independent experiments. * p<0.05.
Fig. 4 is a bar graph illustrating that exogenous CO causes an increase in NF-
oB
activation in hepatocytes. CO = carbon monoxide; Air = room air; BAY = BAY 11-
7082; CM = cytokine mixture (TNF-a (500 U/ml), IL-1(3 (100 U/ml), and IFN-8
(100
U/ml)). Results shown are the mean ~ SE of triplicate wells from three
independent
2o experiments. *p<0.001 versus Air.
Fig. 5 is a picture of a polyacrylamide gel illustrating that exogenous CO
induces an increase in NF-xB nuclear translocation and DNA binding as measured
by
electrophoretic mobility shift assay (EMSA). FP = free probe (no nuclear
protein, thus
no DNA binding); TOTAL = NFkB bands without antibody supershifting.
25 Figs. 6A-6C are photomicrographs of primary hepatocytes immunostained to
detect nuclear p65 localization, illustrating that exogenous CO causes an
increase in
NF-xB activation in hepatocytes. Fig. 6A: air-exposed hepatocytes. Fig. 6B:
hepatocytes exposed to cytokine mixture (TNF-a (500 U/ml), IL-1(3 (100 U/ml),
and
1FN-8 (100 U/ml)). Fig. 6C: CO-exposed hepatocytes. Images are representative
of 6
3o different fields. Bar represents 10 p.m.
Fig. 7 is a bar graph illustrating that exogenous CO-induced protection of
hepatocytes involves NF-oB-dependent iNOS expression. CO = carbon monoxide;
Air = room air; BAY = BAY 11-7082; CM = cytokine mixture. Results shown are
the
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
mean ~ SE of triplicate wells from four independent experiments. *p<0.001
versus air
and air/BAY-treated cells.
Fig. 8 is a picture of a Western blot illustrating that iNOS protein
expression in
hepatocytes is markedly increased by exposure to TNF-a in the presence of CO
as
s compared to exposure to TNF-a alone. iNOS = inducible nitric oxide synthase;
CO =
carbon monoxide; Air = room air; TNF = TNF-a/ActD; (3-Actin = control protein.
The
immunoblot is representative of 3 independent experiments.
Fig. 9 is a bar graph illustrating that iNOS activity-deficient mouse (inos ~-
)
hepatocytes are not protected by CO against TNF-a-induced cell death. CO =
carbon
1 o monoxide; Air = room air; TNF = TNF-a/ActD; inos ~- = iNOS knockout mice;
L-NIO
= L-N5-(1-iminoethyl)-ornithine-2HCl. Results shown are the mean ~ SE of
triplicate
wells from four independent experiments. *p<0.01 versus non-TNF/ActD and
CO/TNF/ActD-treated cells.
Fig. 10 is a bar graph illustrating that exogenously-administered CO prevents
i5 TNF-a/D-Gal-induced liver injury in mice. ALT = serum alanine
aminotransferase;
CO = carbon monoxide; Air = room air. Results presented as mean ~ SD of 18-20
mice. *p<0.001 versus air-treated.
Figs. 11A-11H are photomicrographs of liver samples illustrating that
exogenously-administered CO prevents TNF-a/D-Gal-induced liver injury in mice.
2o Figs. 11A and 11B: liver samples from mice exposed to room air and CO,
respectively,
and stained with hematoxylin & eosin (H & E). Figs. 11C and 11D: liver samples
from
TNF-a/D-Gal-treated mice exposed to room air and CO, respectively, and stained
with
H & E. Figs. 11E and 11F: liver samples from TNF-a/D-Gal-treated mice exposed
to
room air and CO, respectively, and stained to detect activated caspase-3.
Figs. 11G and
2s 11H: liver samples from TNF-a/D-Gal-treated mice exposed to room air and
CO,
respectively, and stained using terminal deoxynucleotidyl transferase mediated
dUTP
nick end labeling (TUNEL). Images are representative sections from 15-20
sections/liver from 3-4 individual mice/group. Bar represents 20 ~.m.
Fig. 12 is a picture of a Western blot illustrating that livers of mice
exposed to
3o TNF-a/D-Gal and treated with inhaled CO display increased iNOS protein
levels. Wild
type = wild type mice; iNOS-~- = iNOS deficient mice; CO = carbon monoxide;
Air =
room air; TNF = TNF-a/D-Gal; (3-Actin = control protein.
6
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Figs 13A-13D are photomicrographs of liver samples illustrating that the
livers
of mice exposed to TNF-a/D-Gal and treated with inhaled CO display increased
iNOS
protein levels. Fig. 13A: liver sample from room air-exposed mouse. Fig. 13B:
liver
sample from CO-exposed mouse. Fig. 13C: liver sample from mouse exposed to TNF-
a/D-Gal and room air. Fig. 13D: liver sample from mouse exposed to TNF-a/D-Gal
and CO. Images are representative of 6 separate animals and 6-10 different
sections/liver sample. Bar represents 20 pm.
Fig. 14 is a bar graph illustrating that CO does not protect against liver
damage
in the absence of iNOS function/expression. L-NIL = L-N6-(1-iminoethyl)-lysine-
io dihydrochloride (a selective inhibitor of iNOS); CO = carbon monoxide; Air
= room
air; TNF = TNF-a/D-Gal. Results are mean ~ SD of 6-8 animals/group. *p<0.01
versus CO/TNF-a!D-gal and air and CO controls.
Fig. 15 is a picture of a Western blot illustrating that the livers of CO-
treated
mice displayed increased expression of HO-1 in both the presence and absence
of TNF-
a1D-Gal.
CO = carbon monoxide; Air = room air; TNF = TNF-a/D-Gal; (3-Actin = control
protein. Blot is representative of 2 independent experiments.
Fig. 16 is a picture of a Western blot illustrating that the livers of CO-
treated
mice do not display increased expression of HO-1 in the presence or absence of
TNF-
2o a/D-Gal if iNOS is inhibited using L-NIL. CO = carbon monoxide; Air = room
air;
TNF = TNF-a/D-Gal; ~i-Actin = control protein; L-NIL = L-N6-(1-iminoethyl)-
lysine-
dihydrochloride (a selective inhibitor of iNOS). Blot is representative of 2
independent
experiments.
Fig. 17 is a bar graph illustrating that CO-induced HO-1 is protective against
TNF-a-induced liver damage in mice. ALT = serum alanine aminotransferase; Air
=
room air; TNF = TNF-a/D-Gal; Sn = tin protoporphyrin (an inhibitor of HO-1);
VP =
V-PYRRO (a nitric oxide donor). Results are expressed as mean ~ SD of 8-10
mice/group. *p< 0.05 versus CO/TNF/D-gal-treated mice.
Fig. 18 is a bar graph illustrating that induction of HO-1 is protective
against
3o TNF-a-induced liver injury independent of iNOS activity. ALT = serum
alanine
aminotransferase; Air = room air; TNF = TNF-a/D-Gal; L-NIL = L-N6-(1-
iminoethyl)-
lysine-dihydrochloride (a selective inhibitor of iNOS); CoPP = cobalt
protoporphyrin
7
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
(an inducer of HO-1); iNOS-~- = iNOS deficient mice. Results are mean ~ SD of
6-8
mice/group. *p<0.001 versus Air/TNF and L-NIL/TNF.
Fig. 19 is bar graph illustrating that HO-1 expression is required for CO-
induced protection of mouse hepatocytes from TNF-a/ActD-induced cell death.
Wild
s type (black bars) = hepatocytes isolated from wild type C57BL/6J mice; hmox-
1-~-
(white bars) = hepatocytes isolated from HO-1 null mice; CO = carbon monoxide;
Air
= room air; TNF-a = TNF-a/ActD. *p<0.01 versus non- TNF-a/ActD treated cells
and
versus TNF-a/ActD-treated cells that were also treated with CO.
Fig. 20 is bar graph illustrating that HO-1 expression is required for NO-
io induced protection of mouse hepatocytes from TNF-a/ActD-induced cell death.
Wild
type (black bars) = hepatocytes isolated from wild type C57BIJ6J mice; hmox-1-
~
(white bars) = hepatocytes isolated from HO-1 null mice; SNAP = s-nitroso-N-
acetyl-
penicillamine (an NO donor); Air = room air; TNF-a = TNF-a/ActD. *p<0.01
versus
non-TNF-a/ActD treated cells and versus TNF-a/ActD-treated cells that were
also
treated with NO.
Fig. 21 is a bar graph illustrating that CO-exposed mice were protected from
acetaminophen-induced liver injury. ALT = serum alanine aminotransferase; Air
=
room air; APAP = acetaminophen. Results are mean ~SD of 4-8 mice/group.
2o DETAILED DESCRIPTION
The term "carbon monoxide" (or "CO") as used herein describes molecular
carbon monoxide in its gaseous state, compressed into liquid form, or
dissolved in
aqueous solution. The terms "carbon monoxide composition" and "pharmaceutical
composition comprising carbon monoxide" is used throughout the specification
to
25 describe a gaseous or liquid composition containing carbon monoxide that
can be
administered to a patient and/or an organ, e.g., the liver. The skilled
practitioner will
recognize which form of the pharmaceutical composition, e.g., gaseous, liquid,
or both
gaseous and liquid forms, is preferred for a given application.
The terms "effective amount" and "effective to treat," as used herein, refer
to
3o an amount or concentration of carbon monoxide utilized for period of time
(including
acute or chronic administration and periodic or continuous administration)
that is
effective within the context of its administration for causing an intended
effect or
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
physiological outcome. Effective amounts of carbon monoxide for use in the
present
invention include, for example, amounts that prevent hepatitis, reduce the
risk of
hepatitis, reduce the symptoms of hepatitis, or improve the outcome of other
hepatitis
treatments.
s For gases, effective amounts of carbon monoxide generally fall within the
range
of about 0.0000001% to about 0.3% by weight, e.g., 0.0001% to about 0.25% by
weight, preferably at least about 0.001%, e.g., at least 0.005%, 0.010%,
0.02%,
0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or
0.24%
by weight carbon monoxide. Preferred ranges include, e.g., 0.001% to about
0.24%,
io about 0.005% to about 0.22%, about 0.005% to about 0.05%, about 0.010% to
about
0.20%, about 0.02% to about 0.15%, about 0.025% to about 0.10%, or about 0.03%
to
about 0.08%, or about 0.04% to about 0.06%. For liquid solutions of CO,
effective
amounts generally fall within the range of about 0.0001 to about 0.0044 g
CO/100 g
liquid, e.g., at least 0.0001, 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013,
0.0014,
15 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028,
0.0030,
0.0032, 0.0035, 0.0037, 0.0040, or 0.0042 g CO/100 g aqueous solution.
Preferred
ranges include, e.g., about 0.0010 to about 0.0030 g CO/100 g liquid, about
0.0015 to
about 0.0026 g CO/100 g liquid, or about 0.0018 to about 0.0024 g CO/100 g
liquid.
A skilled practitioner will appreciate that amounts outside of these ranges
may be used,
2o depending upon the application.
The term "patient" is used throughout the specification to describe an animal,
human or non-human, to whom treatment according to the methods of the present
invention is provided. Veterinary applications are contemplated by the present
invention. The term includes but is not limited to mammals, e.g., humans,
other
25 primates, pigs, rodents such as mice and rats, rabbits, guinea pigs,
hamsters, cows,
horses, cats, dogs, sheep and goats. The term "treat(ment)," is used herein to
describe
delaying the onset of, inhibiting, or alleviating the effects of a condition,
e.g., hepatitis,
in a patient.
The term "hepatitis" is an art-recognized term and is used herein to refer to
a
3o disease of patients characterized in part by inflammation of the liver.
Causative agents
of hepatitis include, for example, infections, e.g., infection with specific
hepatitis
viruses, e.g., hepatitis A, B, C, D, E, and G viruses; or hepatotoxic agents,
e.g.,
hepatotoxic drugs (e.g., isoniazid, methyldopa, acetaminophen, amiodarone, and
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
nitrofurantoin), and toxins (e.g., endotoxin or environmental toxins).
Hepatitis may
occur postoperatively in liver transplantation patients. Further examples of
drugs and
toxins that may cause hepatitis (i.e., hepatotoxic agents) are described in
Feldman:
Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed., Chapter
17 (Liver
Disease Caused by Drugs, Anesthetics, and Toxins), the contents of which are
expressly incorporated herein by reference in their entirety. Such examples
include, but
are not limited to, methyldopa and phenytoin, barbiturates, e.g.,
phenobarbital;
sulfonamides (e.g., in combination drugs such as co-trimoxazole
(sulfamethoxazole and
trimethoprim); sulfasalazine; salicylates; disulfiram; (3-adrenergic blpcking
agents e.g.,
acebutolol, labetalol, and metoprolol); calcium channel blockers,
e.g., nifedipine, verapamil, and diltiazem; synthetic retinoids, e.g.,
etretinate; gastric
acid suppression drugs e.g., oxmetidine, ebrotidine, cimetidine, ranitidine,
omeprazole
and famotidine; leukotriene receptor antagonists, e.g., zafirlukast; anti-
tuberculous
drugs,
e.g., rifampicin and pyrazinamide; antifungal agents, e.g., ketoconazole,
terbinafine,
fluconazole, and itraconazole; antidiabetic drugs, e.g., thiazolidinediones,
e.g.,
troglitazone and rosiglitazone; drugs used in neurologic disorders, e.g.,
neuroleptic
agents, antidepressants (e.g., fluoxetine, paroxetine, venlafaxine, trazodone,
tolcapone,
and nefazodone), hypnotics (e.g., alpidem, zolpidem, and bentazepam), and
other
2o drugs, e.g., tacrine, dantrolene, riluzole, tizanidine, and alverine;
nonsteroidal anti-
inflammatory drugs, e.g., bromfenac; COX-2 inhibitors; cyproterone acetate;
leflunomide; antiviral agents, e.g., fialuridine, didanosine, zalcitabine,
stavudine,
lamivudine, zidovudine, abacavir; anticancer drugs, e.g., tamoxifen and
methotrexate;
recreational drugs, e.g., cocaine, phencyclidine, and 5-methoxy-3,4-
methylenedioxymethamphetamine; L-asparaginase; amodiaquine; hycanthone;
anesthetic agents; e.g., halothane, enflurane, and isoflurane; vitamins e.g.,
vitamin A;
and dietary and/or environmental toxins, e.g., pyrrolizidine alkaloids, toxin
from
Amanita phalloides or other toxic mushrooms, aflatoxin, arsenic, Bordeaux
mixture
(copper salts and lime), vinyl chloride monomer; carbon tetrachloride,
beryllium,
3o dimethylformamide, dimethylnitrosamine, methylenedianiline, phosphorus,
chlordecone (Kepone), 2,3,7,8-tetrachloro-dibenzo p-dioxin (TCDD),
tetrachloroethane, tetrachloroethylene, 2,4,5-trinitrotoluene, 1,1,1-
trichloroethane,
toluene, and xylene, and known "herbal remedies," e.g., ephedrine and eugenol.
to
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Symptoms of hepatitis can include fatigue, loss of appetite, stomach
discomfort,
and/or jaundice (yellowing of the skin andlor eyes). More detailed
descriptions of
hepatitis are provided, for example, in the The Merck Manual of Diagnosis and
Therapy, 17'h Edition, Section 4, Chapter 42, Section 4, Chapter 44, and
Section 4,
Chapter 40, the contents of which are expressly incorporated herein by
reference in
their entirety.
Skilled practitioners will appreciate that a patient can be diagnosed by a
physician as suffering from hepatitis by any method known in the art, e.g., by
assessing
liver function, e.g., using blood tests for serum alanine aminotransferase
(ALT) levels,
alkaline phosphatase (AP), or bilirubin levels.
Individuals considered at risk for developing hepatitis may benefit
particularly
from the invention, primarily because prophylactic treatment can begin before
there is
any evidence of hepatitis. Individuals "at risk" include, e.g., patients
infected with
hepatitis viruses, or individuals suffering from any of the conditions or
having the risk
15 factors described herein (e.g., patients exposed to hepatotoxic agents).
The skilled
practitioner will appreciate that a patient can be determined to be at risk
for hepatitis by
a physician's diagnosis.
Amounts of CO effective to treat hepatitis can be administered to a patient on
the day the patient is diagnosed as suffering from hepatitis or any condition
associated
2o with hepatitis, or as having any risk factor associated with an increased
likelihood that
the patient will develop hepatitis (e.g., that the patient has recently been,
is being, or
will be exposed to a hepatotoxic agent, e.g., a hepatotoxic drug such as
acetaminophen). Patients can inhale CO at concentrations ranging from 10 ppm
to
1000 ppm, e.g., about 100 ppm to about 800 ppm, about 150 ppm to about 600
ppm, or
25 about 200 ppm to about 500 ppm. Preferred concentrations include, e.g.,
about 30
ppm, 50 ppm, 75 ppm, 100 ppm, 125 ppm, 200 ppm, 250 ppm, 500 ppm, 750 ppm, or
about 1000 ppm. CO can be administered to the patient intermittently or
continuously.
CO can be administered for about l, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, or
greater
than 20 days, e.g., 1 2, 3, 5, or 6 months, or until the patient no longer
exhibits
3o symptoms of hepatitis, or until the patient is diagnosed as no longer being
at risk for
hepatitis. In a given day, CO can be administered continuously for the entire
day, or
intermittently, e.g., a single whiff of CO per day (where a high concentration
is used),
or for up to 23 hours per day, e.g., up to 20, 15, 12, 10, 6, 3, or 2 hours
per day, or up
11
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
to 1 hour per day.
If the patient needs to be treated with a hepatotoxic drug (e.g., because
prescribed by a physician), the patient can be treated with CO (e.g., a
gaseous CO
composition) before, during, and/or after administration of the drug. For
example, CO
can be administered to the patient, intermittently or continuously, starting 0
to 20 days
before the drug is administered (and where multiple doses are given, before
each
individual dose), e.g., starting at least about 30 minutes, e.g., about 1, 2,
3, 5, 7, or 10
hours, or about 1, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, or greater than 20
days, before
the administration. Alternatively or in addition, CO can be administered to
the patient
1 o concurrent with administration of the drug. Alternatively or in addition,
CO can be
administered to the patient after administration of the drug, e.g., starting
immediately
after administration, and continuing intermittently or continuously for about
1, 2, 3, 5,
7, or 10 hours, or about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, indefinitely,
or until a
physician determines that administration of CO is no longer necessary (e.g.,
after the
15 hepatotoxic drug is eliminated from the body or can no longer cause damage
to the
liver).
Preparation of Gaseous Compositions
A carbon monoxide composition may be a gaseous carbon monoxide
2o composition. Compressed or pressurized gas useful in the methods of the
invention can
be obtained from any commercial source and in any type of vessel appropriate
for
storing compressed gas. For example, compressed or pressurized gases can be
obtained
from any source that supplies compressed gases, such as oxygen, for medical
use. The
term "medical grade" gas, as used herein, refers to gas suitable for
administration to
2s patients as defined herein. The pressurized gas including CO used in the
methods of
the present invention can be provided such that all gases of the desired final
composition (e.g., CO, He, NO, COZ, 02, NZ) are in the same vessel, except
that NO
and 02 cannot be stored together. Optionally, the methods of the present
invention can
be performed using multiple vessels containing individual gases. For example,
a single
3o vessel can be provided that contains carbon monoxide, with or without other
gases, the
contents of which can be optionally mixed with room air or with the contents
of other
vessels, e.g., vessels containing oxygen, nitrogen, carbon dioxide, compressed
air, or
any other suitable gas or mixtures thereof.
12
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Gaseous compositions administered to a patient according to the present
invention typically contain 0% to about 79% by weight nitrogen, about 21% to
about
100% by weight oxygen and about 0.0000001% to about 0.3% by weight
(corresponding to about 1 ppb or 0.001 ppm to about 3,000 ppm) carbon
monoxide.
Preferably, the amount of nitrogen in the gaseous composition is about 79% by
weight,
the amount of oxygen is about 21% by weight and the amount of carbon monoxide
is
about 0.0001% to about 0.25% by weight, preferably at least about 0.001%,
e.g., at
least about 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%,
0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight. Preferred ranges of carbon
1 o monoxide include about 0.005% to about 0.24%, about 0.01 % to about 0.22%,
about
0.015% to about 0.20%, about 0.08% to about 0.20%, and about 0.025% to about
0.1%
by weight. It is noted that gaseous carbon monoxide compositions having
concentrations of carbon monoxide greater than 0.3% (such as 1070 or greater)
may be
used for short periods (e.g., one or a few breaths), depending upon the
application.
15 A gaseous carbon monoxide composition may be used to create an atmosphere
that comprises carbon monoxide gas. An atmosphere that includes appropriate
levels
of carbon monoxide gas can be created, for example, by providing a vessel
containing a
pressurized gas comprising carbon monoxide gas, and releasing the pressurized
gas
from the vessel into a chamber or space to form an atmosphere that includes
the carbon
2o monoxide gas inside the chamber or space. Alternatively, the gases can be
released
into an apparatus that culminates in a breathing mask or breathing tube,
thereby
creating an atmosphere comprising carbon monoxide gas in the breathing mask or
breathing tube, ensuring the patient is the only person in the room exposed to
significant levels of carbon monoxide.
25 Carbon monoxide levels in an atmosphere can be measured or monitored using
any method known in the art. Such methods include electrochemical detection,
gas
chromatography, radioisotope counting, infrared absorption, colorimetry, and
electrochemical methods based on selective membranes (see, e.g., Sunderman et
al.,
Clin. Chem. 28:2026-2032, 1982; Ingi et al., Neuron 16:835-842, 1996). Sub-
parts per
3o million carbon monoxide levels can be detected by, e.g., gas chromatography
and
radioisotope counting. Further, it is known in the art that carbon monoxide
levels in the
sub-ppm range can be measured in biological tissue by a midinfrared gas sensor
(see,
e.g., Morimoto et al., Am. J. Physiol. Heart. Circ. Physiol 280:H482-H488,
2001).
13
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Carbon monoxide sensors and gas detection devices are widely available from
many
commercial sources.
Preparation of Liquid Compositions
s A carbon monoxide composition may also be a liquid carbon monoxide
composition. A liquid can be made into a carbon monoxide composition by any
method known in the art for causing gases to become dissolved in liquids. For
example, the liquid can be placed in a so-called "C02 incubator" and exposed
to a
continuous flow of carbon monoxide, preferably balanced with carbon dioxide,
until a
desired concentration of carbon monoxide is reached in the liquid. As another
example, carbon monoxide gas can be "bubbled" directly into the liquid until
the
desired concentration of carbon monoxide in the liquid is reached. The amount
of
carbon monoxide that can be dissolved in a given aqueous solution increases
with
decreasing temperature. As still another example, an appropriate liquid may be
passed
~ 5 through tubing that allows gas diffusion, where the tubing runs through an
atmosphere
comprising carbon monoxide (e.g., utilizing a device such as an extracorporeal
membrane oxygenator). The carbon monoxide diffuses into the liquid to create a
liquid
carbon monoxide composition.
It is likely that such a liquid composition intended to be introduced into a
living
2o animal will be at or about 37°C at the time it is introduced into
the animal.
The liquid can be any liquid known to those of skill in the art to be suitable
for
administration to patients (see, for example, Oxford Textbook of Surgery,
Morns and
Malt, Eds., Oxford University Press (1994)). In general, the liquid will be an
aqueous
solution. Examples of solutions include Phosphate Buffered Saline (PBS),
CelsiorTM,
25 PerfadexTM, Collins solution, citrate solution, and University of Wisconsin
(UW)
solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University
Press
(1994)). In one embodiment of the present invention, the liquid is Ringer's
Solution,
e.g., lactated Ringer's Solution, or any other liquid that can be used infused
into a
patient. In another embodiment, the liquid includes blood, e.g., whole blood.
3o Any suitable liquid can be saturated to a set concentration of carbon
monoxide
via gas diffusers. Alternatively, pre-made solutions that have been quality
controlled to
contain set levels of carbon monoxide can be used. Accurate control of dose
can be
achieved via measurements with a gas permeable, liquid impermeable membrane
14
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
connected to a carbon monoxide analyzer. Solutions can be saturated to desired
effective concentrations and maintained at these levels.
Treatment of Patients with Carbon Monoxide Compositions
A patient can be treated with a carbon monoxide composition by any method
known in the art of administering gases and/or liquids to patients. Carbon
monoxide
compositions can be administered to a patient diagnosed with, or determined to
be at
risk for, hepatitis. The present invention contemplates the systemic
administration of
liquid or gaseous carbon monoxide compositions to patients (e.g., by
inhalation and/or
io ingestion), and the topical administration of the compositions to the
patient's liver (e.g.,
by introduction into the abdominal cavity).
Systemic Delivery of Carbon Monoxide
Gaseous carbon monoxide compositions can be delivered systemically to a
patient, e.g., a patient diagnosed with, or determined to be at risk for
hepatitis. Gaseous
carbon monoxide compositions are typically administered by inhalation through
the
mouth or nasal passages to the lungs, where the carbon monoxide is readily
absorbed
into the patient's bloodstream. The concentration of active compound (CO)
utilized in
the therapeutic gaseous composition will depend on absorption, distribution,
2o inactivation, and excretion (generally, through respiration) rates of the
carbon
monoxide as well as other factors known to those of skill in the art. It is to
be further
understood that for any particular subject, specific dosage regimens should be
adjusted
over time according to the individual need and the professional judgment of
the person
administering or supervising the administration of the compositions, and that
the
25 concentration ranges set forth herein are exemplary only and are not
intended to limit
the scope or practice of the claimed composition. Treatments can be monitored
and CO
dosages can be adjusted to ensure optimal treatment of the patient. Acute, sub-
acute
and chronic administration of carbon monoxide are contemplated by the present
invention, depending upon, e.g., the severity or persistence of hepatitis in
the patient.
3o Carbon monoxide can be delivered to the patient for a time (including
indefinitely)
sufficient to treat the condition and exert the intended pharmacological or
biological
effect.
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
The following are examples of some methods and devices that can be utilized to
administer gaseous carbon monoxide compositions to patients.
Ventilators
Medical grade carbon monoxide (concentrations can vary) can be purchased
mixed with air or another oxygen-containing gas in a standard tank of
compressed gas
(e.g., 21% OZ, 79% NZ). It is non-reactive, and the concentrations that are
required for
the methods of the present invention are well below the combustible range (10%
in air).
In a hospital setting, the gas presumably will be delivered to the bedside
where it will
be mixed with oxygen or house air in a blender to a desired concentration in
ppm (parts
per million). The patient will inhale the gas mixture through a ventilator,
which will be
set to a flow rate based on patient comfort and needs. This is determined by
pulmonary
graphics (i.e., respiratory rate, tidal volumes etc.). Fail-safe mechanisms)
to prevent
the patient from unnecessarily receiving greater than desired amounts of
carbon
monoxide can be designed into the delivery system. The patient's carbon
monoxide
level can be monitored by studying (1) carboxyhemoglobin (COHb), which can be
measured in venous blood, and (2) exhaled carbon monoxide collected from a
side port
of the ventilator. Carbon monoxide exposure can be adjusted based upon the
patient's
health status and on the basis of the markers. If necessary, carbon monoxide
can be
2o washed out of the patient by switching to 100% 02 inhalation. Carbon
monoxide is not
metabolized; thus, whatever is inhaled will ultimately be exhaled except for a
very
small percentage that is converted to CO2. Carbon monoxide can also be mixed
with
any level of OZ to provide therapeutic delivery of carbon monoxide without
consequential hypoxic conditions.
Face Mask and Tent
A carbon monoxide-containing gas mixture is prepared as above to allow
passive inhalation by the patient using a facemask or tent. The concentration
inhaled
can be changed and can be washed out by simply switching over to 100% 02.
so Monitoring of carbon monoxide levels would occur at or near the mask or
tent with a
fail-safe mechanism that would prevent too high of a concentration of carbon
monoxide
from being inhaled.
16
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Portable inhaler
Compressed carbon monoxide can be packaged into a portable inhaler device
and inhaled in a metered dose, for example, to permit intermittent treatment
of a
recipient who is not in a hospital setting. Different concentrations of carbon
monoxide
s could be packaged in the containers. The device could be as simple as a
small tank
(e.g., under 5 kg) of appropriately diluted CO with an on-off valve and a tube
from
which the patient takes a whiff of CO according to a standard regimen or as
needed.
Intravenous Artificial Lung
to An artificial lung (a catheter device for gas exchange in the blood)
designed for
OZ delivery and C02 removal can be used for carbon monoxide delivery. The
catheter,
when implanted, resides in one of the large veins and would be able to deliver
carbon
monoxide at given concentrations either for systemic delivery or at a local
site. The
delivery can be a local delivery of a high concentration of carbon monoxide
for a short
~ 5 period of time at the site of the procedure, e.g., in proximity to the
liver (this high
concentration would rapidly be diluted out in the bloodstream), or a
relatively longer
exposure to a lower concentration of carbon monoxide (see, e.g., Hattler et
al., Artif.
Organs 18(11):806-812 (1994); and Golob et al., ASAIO J., 47(5):432-437
(2001)).
2o Normobaric chamber
In certain instances, it would be desirable to expose the whole patient to
carbon
monoxide. The patient would be inside an airtight chamber that would be
flooded with
carbon monoxide (at a level that does not endanger the patient, or at a level
that poses
an acceptable risk without the risk of bystanders being exposed. Upon
completion of
25 the exposure, the chamber could be flushed with air (e.g., 21% O2, 79% NZ)
and
samples could be analyzed by carbon monoxide analyzers to ensure no carbon
monoxide remains before allowing the patient to exit the exposure system.
Systemic Delivery of Liquid CO Compositions
3o The present invention further contemplates that aqueous solutions
comprising
carbon monoxide can be created for systemic delivery to a patient, e.g., for
oral
delivery and/or by infusion into the patient, e.g., intravenously, intra-
arterially,
intraperitoneally, and/or subcutaneously. For example, liquid CO compositions,
such
17
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
as CO-saturated Ringer's Solution, can be infused into a patient suffering
from or at
risk for hepatitis. Alternatively or in addition, CO-partially or completely
saturated
whole (or partial) blood can be infused into the patient.
The present invention also contemplates that agents capable of delivering
doses
s of gaseous CO compositions or liquid CO compositions can be utilized (e.g.,
CO-
releasing gums, creams, ointments, lozenges, or patches).
Topical Treatment of Organs with Carbon Monoxide
Alternatively or in addition, carbon monoxide compositions can be applied
directly to the liver, e.g., to the entire liver, or to any portion thereof. A
gaseous
composition can be directly applied to the liver of a patient by any method
known in
the art for insufflating gases into a patient. For example, gases, e.g.,
carbon dioxide,
are often insufflated into the abdominal cavity of patients to facilitate
examination
during laproscopic procedures (see, e.g., Oxford Textbook of Surgery, Morris
and Malt,
15 Eds., Oxford University Press (1994)). The skilled practitioner will
appreciate that
similar procedures could be used to administer carbon monoxide compositions
directly
to the liver of a patient.
Aqueous carbon monoxide compositions can also be administered topically to
the liver of a patient. Aqueous forms of the compositions can be administered
by any
2o method known in the art for administering liquids to patients. As with
gaseous
compositions, aqueous compositions can be applied directly to the liver. For
example,
liquids, e.g., saline solutions containing dissolved CO, can be injected into
the
abdominal cavity of patients during laproscopic procedures. The skilled
practitioner
will appreciate that similar procedures could be used to administer liquid
carbon
25 monoxide compositions directly to the liver of a patient. Further, an in
situ exposure
can be carned out by flushing the liver or a portion thereof with a liquid
carbon
monoxide composition (see Oxford Textbook of Surgery, Morns and Malt, Eds.,
Oxford University Press (1994)).
30 Use of Hemoxy~enase-l, Other Compounds, and Other Treatments for Hepatitis
Also contemplated by the present invention is the induction or expression of
hemeoxygenase-1 (HO-1) in conjunction with administration of CO. For example,
HO-1 can be induced in a patient suffering from or at risk for hepatitis. As
used herein,
18
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
the term "induce(d)" means to cause increased production of a protein, e.g.,
HO-1, in
isolated cells or the cells of a tissue, organ or animal using the cells' own
endogenous
(e.g., non-recombinant) gene that encodes the protein.
HO-1 can be induced in a patient by any method known in the art. For example,
production of HO-1 can be induced by hemin, by iron protoporphyrin, or by
cobalt
protoporphyrin. A variety of non-heme agents including heavy metals,
cytokines,
hormones, NO, COCl2, endotoxin and heat shock are also strong inducers of HO-1
expression (Choi et al., Am. J. Respir. Cell Mol. Biol. 15:9-19, 1996; Maines,
Annu.
Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Tenhunen et al., J. Lab. Clin.
Med.
75:410-421, 1970). HO-1 is also highly induced by a variety of agents causing
oxidative stress, including hydrogen peroxide, glutathione depletors, UV
irradiation,
endotoxin and hyperoxia (Choi et al., Am. J. Respir. Cell Mol. Biol. 15:9-19,
1996;
Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Keyse et al.,
Proc.
Natl. Acad. Sci. USA 86:99-103, 1989). A "pharmaceutical composition
comprising
an inducer of HO-1" means a pharmaceutical composition containing any agent
capable
of inducing HO-1 in a patient, e.g., any of the agents described above, e.g.,
NO, heroin,
iron protoporphyrin, and/or cobalt protoporphyrin.
HO-1 expression in a cell can be increased via gene transfer. As used herein,
the term "express(ed)" means to cause increased production of a protein, e.g.,
HO-1 or
2o ferritin, in isolated cells or the cells of a tissue, organ or animal using
an exogenously
administered gene (e.g., a recombinant gene). The HO-1 or ferritin is
preferably of the
same species (e.g., human, mouse, rat, etc.) as the recipient, in order to
minimize any
immune reaction. Expression could be driven by a constitutive promoter (e.g.,
cytomegalovirus promoters) or a tissue-specific promoter (e.g., milk whey
promoter for
2s mammary cells or albumin promoter for liver cells). An appropriate gene
therapy
vector (e.g., retrovirus, adenovirus, adeno associated virus (AAV), pox (e.g.,
vaccinia)
virus, human immunodeficiency virus (HIV), the minute virus of mice, hepatitis
B
virus, influenza virus, Herpes Simplex Virus-1, and lentivirus) encoding HO-1
or
ferritin would be administered to a patient suffering from or at risk for
hepatitis, by
so mouth, by inhalation, or by injection into the liver. Similarly, plasmid
vectors encoding
HO-1 or apoferntin can be administered, e.g., as naked DNA, in liposomes, or
in
microparticles.
19
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Further, exogenous HO-1 protein can be directly administered to a patient by
any method known in the art. Exogenous HO-1 can be directly administered in
addition, or as an alternative, to the induction or expression of HO-1 in the
patient as
described above. The HO-1 protein can be delivered to a patient, for example,
in
liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see,
e.g., Becker-
Hapak et al., Methods 24:247-256, 2001).
Alternatively or in addition, any of the products of metabolism by HO-1, e.g.,
bilirubin, biliverdin, iron, and/or ferritin, can be administered to a patient
in conjunction
with CO in order to prevent or treat hepatitis. Further, the present invention
1 o contemplates that iron-binding molecules other than ferritin, e.g.,
desferoxamine
(DFO), iron dextran, and/or apoferritin, can be administered to the patient.
Further still,
the present invention contemplates that enzymes (e.g., biliverdin reductase)
that
catalyze the breakdown any of these products can be inhibited to
create/enhance the
desired effect. Any of the above can be administered, e.g., orally,
intravenously,
intraperitoneally, or by direct administration to the liver.
The present invention contemplates that compounds that release CO into the
body after administration of the compound (e.g., CO-releasing compounds, e.g.,
photoactivatable CO-releasing compounds), e.g., dimanganese decacarbonyl,
tricarbonyldichlororuthenium (II) dimer, and methylene chloride (e.g., at a
dose of
2o between 400 to 600 mglkg, e.g., about SOOmg/kg), can also be used in the
methods of
the present invention, as can carboxyhemoglobin and CO-donating hemoglobin
substitutes.
The above can be administered to a patient in any way, e.g., by oral,
intraperitoneal, intravenous, or intraarterial administration. Any of the
above
2s compounds can be administered to the patient locally and/or systemically,
and in any
combination.
The present invention further contemplates treating/preventing hepatitis by
administering CO to the patient in combination with any other known methods or
compounds for treating hepatitis, e.g., cessation or reducing administration
of causative
3o drugs; administering corticosteroids and/or a-interferon or other antiviral
agents to the
patient; andlor performing surgery on the patient, e.g., liver
transplantation.
The invention is illustrated in part by the following examples, which are not
to
be taken as limiting the invention in any way.
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Example 1. Carbon Monoxide Attenuates Liver Injury
Animals
Male C57BL/6J (Charles Rivers Laboratories, Bar Harbor, ME), 8-12-wk-old
inos-~- mice and wild type littermates (bred/maintained at the University of
Pittsburgh)
were used for in vivo experiments.
Acute hepatic injury models
Groups of mice were administered TNF-a/D-gal (0.3 p.g/8mg/mouse, i.p.,
io respectively). Depending on the experimental condition, some mice received
CO (250
ppm), the selective NO donor OZ-vinyl 1-(pyrrolidin-1-yl) diazen-1-ium-1,2-
diolate (V-
PYRRO; 10 mg/kg subcutaneously (s.c.), Alexis Biochem., San Diego, CA) or
cobalt
protoporphyrin (CoPP, 5 mg/kg, intraperitoneally (i.p.), Frontier Scientific,
Logan,
UT). Additionally, the selective inhibitor of iNOS L-N6-(1-iminoethyl)-lysine-
dihydrochloride (L-NIL; 5 mg/kg, i.p., Alexis Biochemicals) or the HO-1
inhibitor tin
protoporphyrin (SnPP; 50 pmol/kg, i.p., Frontier Scientific) was administered
when
specified. Where indicated, acetaminophen (Sigma Chem. Co.; St Louis, MO) was
administered (500 mg/kg, i.p.).
2o Hepatocyte cell culture.
Mouse primary hepatocytes were harvested from C57BL/6J, mkk3-~ , inos ~ (in-
house breeding colony), or hmox-1-~- mice as described in Kim et al. (J. Biol.
Chem.
272: 1402-1411 (1997)). Hepatocytes were used on days 1-3 following harvest.
Induction of hepatocyte death/apoptosis
Cells were treated with TNF-a (lOng/ml) and actinomycin-D (Act-D; 200
ng/ml, Sigma Chemical Co. St. Louis, MO) to induce cell death. TNF-a/ActD
treatment has been demonstrated to induce cell death, specifically apoptosis,
in primary
hepatocytes (see, e.g., Kim et al. (J.Biol.Chem. 272: 1402-1411 (1997)).
Hepatocytes
so were treated with CO, the NO donor s-nitroso-N-acetyl-penicillamine (SNAP;
250-750
N.M), and/or additional pharmacologic agents where indicated. Twelve hours
after
TNF-a/ActD treatment, cells were washed and stained with crystal violet to
determine
viability as previously described (Id.). Where indicated, the selective in
vitro inhibitor
21
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
of iNOS, L-NS-(1-iminoethyl)-ornithine-2HC1 (LNIO;I-2 mM; Calbiochem, San
Diego, CA) was administered.
Gene transfer/plasmids.
In some experiments, gene transfer of an IKBa superrepressor (Hellerbrand et
al., Hepatology 27:1285-1295 (1998)) or (3-galactosidase using adenoviral
vectors (10
pfu/cell) was performed 12 hours prior to TNF-a/ActD treatment. NF-KB
activation
was evaluated using a luciferase reporter assay as described in Chow et al.
(J. Biol.
Chem. 274: 10689-10692 (1999)). Briefly, hepatocytes were co-transfected with
NF-
KB reporter constructs (pGL3-kappa(3 luciferase, 100 ng/well; and pIEP-Lac-z
0.5 pg
/well) using LipofectinTM (Invitrogen, Carlsbad, CA) as instructed by the
manufacturer.
Evaluation of iNOS expression was performed using a luciferase reporter assay
as
described in Lowenstein et al. (Proc.Natl.Acad.Sci. U.S.A 90: 9730-9734
(1993)).
Briefly, hepatocytes were co-transfected with iNOS promoter reporter
constructs
(pXP2; 1 pg/well) and pIEP-LacZ (0.5 pg/well) as described above.
Luciferase reporter assays
Hepatocytes were transfected with plasmids as described above and treated with
various stimuli 24 hours after transfection. Luciferase activity (reported as
arbitrary
2o units; A.U.) was assayed 6 hours after initiation of treatment, using a
luciferase assay
kit (Promega, Madison, WI) and a Berthold Luminometer. Results were corrected
for
transfection efficiency and protein concentration.
Electrophoretic mobility shift assay
Nuclei were extracted from hepatocytes following treatment. A double-
stranded DNA NF-KB consensus sequence (GGGGACTTTCCC (SEQ ID NO:1 ));
Santa Cruz Biotechnology, Santa Cruz, CA) was labelled with [8-3ZP]-ATP and
incubated with 5 mg of total nuclear protein. Some incubations were performed
in the
presence of antibodies against p65/ReIA or p50 (Santa Cruz Biotech) to
evaluate for
3o supershift. Electrophoretic mobility shift assay (EMSAs) were performed as
described
in Taylor et al. (J.Biol.Chem.273:15148-15156 (1998)).
22
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Immunoblot analysis
Western blot analysis was performed on primary hepatocytes in culture or from
liver homogenates with antibodies to iNOS (Transduction Laboratories,
Lexington,
Kentucky; 1:1000), HO-1 (Calbiochem; 1:2000), or (3-actin (Sigma Chemical;
1:5000).
Thirty pg protein in cell culture experiments or 100 ~g protein from liver
homogenates
was loaded per well for SDS-PAGE.
Histology/Immunohistochemistry
For histology and immunohistochemistry, livers were fixed in 2%
paraformaldehyde and then snap frozen in liquid nitrogen. Livers were then
sectioned
(7 microns thick) and stained with hematoxylin and eosin (H&E). Liver sections
were
also stained for TUNEL and activated caspase-3 using kits according to the
manufacturer's instructions (Promega). Sections for iNOS immunocytochemistry
were
blocked with 5% goat serum containing 0.2% bovine serum albumin. Thereafter,
~ 5 sections were incubated for 1 hour at room temperature with anti-iNOS
antibody
(Transduction Laboratories; 1:300), then washed and probed with a secondary
antibody
conjugated to Alexa-488 (Molecular Probes, Eugene, OR). Nuclei were stained
with
Hoechst dye. Images were acquired using an Olympus Provus microscope.
Hepatocytes in culture were plated on gelatinized coverslips, stimulated as
indicated,
2o and then fixed in 2% paraformaldehyde containing 0.1% Triton X-100.
Blocking and
staining was similar to liver sections except anti-p65/ReIA antibody (Santa
Cruz
Biotechnology; 1:350) was utilized.
CO exposure
25 The animals were exposed to CO at a concentration of 250 ppm. Briefly, 1%
CO in air was mixed with air (21% oxygen) in a stainless steel mixing cylinder
and
then directed into a 3.70 ft3 glass exposure chamber at a flow rate of 12
L/min. A CO
analyzer (Interscan, Chatsworth, CA) was used to measure CO levels
continuously in
the chamber. CO concentrations were maintained at 250 ppm at all times. Mice
were
3o placed in the exposure chamber as required.
HO-1 protects against liver injury.
23
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Whether HO-1 is protective against acute hepatic failure was investigated. The
results are presented in Fig. 1. Cobalt protoporphyrin (5 mg/kg, i.p.) was
administered
to male C57BL/6J mice. Twenty-four hours later, TNF-a/D-gal (0.3 pg/8mg/mouse,
i.p., respectively) was administered to the mice. Serum alanine
aminotransferase
(ALT) levels in the mice were measured 8 hours after administration of TNF-a/D-
gal.
Induction of HO-1 prevented liver injury as measured by serum ALT levels.
Exogenous CO protects hepatocytes
Whether exogenous CO is protective against hepatocyte cell death in vitro was
investigated. The results are presented in Figs. 2 and 3. To generate the data
presented
in Fig. 2, mouse hepatocytes were pre-incubated with CO (250 ppm) for 1 hr
(standard
pre-treatment time for all experiments) prior to addition of TNF-a/Act-D (10
ng/200
ng/ml respectively). Cells were maintained in CO for the duration of the
experiment.
Twelve hours afterward, cell viability was measured as described in Kim et al.
(J. Biol.
~5 Chem. 272: 1402-1411 (1997)). Adenoviral experiments involved incubating
hepatocytes overnight with 10 pfu/cell of the adenovirus prior to addition of
TNF-
a/ActD, and then assaying for viability using crystal violet. The roles of
signaling
molecules guanylyl cyclase and p38 MAPK were also investigated in this model.
To
evaluate the role of cGMP and confirm the role of NF-KB, hepatocytes were
treated
2o separately with the soluble guanylate cyclase (sGC) inhibitor 1H-
[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; Calbiochem; 2-10 pM) or the NF-
KB
inhibitor BAY 11-7082, (1 OpM). Cells were treated with the inhibitors for 1
hour prior
to the 1 hour pretreatment with CO. TNF-a/ActD was then added and the cells
tested
for viability 12 hours later. NF-KB activation was critical to the protection
elicited by
25 CO while cGMP was not involved. Exposure to CO led to significantly less
cell death
(*p<0.01) than without CO.
To generate the data presented in Fig. 3, human primary hepatocytes obtained
from a donor liver resection were treated with CO and TNF-a/ActD as described
above.
Exposure of primary mouse, rat, and human hepatocytes to CO inhibited TNF-a
3o induced apoptosis. Inhibition of hepatocyte apoptosis was independent of
cGMP
generation, as the selective guanylyl cyclase inhibitor ODQ did not reverse
the
protection provided by CO (Fig. 2). Additionally, CO treatment inhibited cell
death
both in the presence of SB203580 (3-30 pM, Calbiochem), a selective inhibitor
of p38
24
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
MAPK activation, and in hepatocytes from rnkk3-~ mice, the dominant upstream
kinase
for p38 (data not shown). Thus, the effects of CO were
independent of the cGMP/p38 MAPK pathway. In these experiments, hepatocytes
were pre-treated with CO for one hour prior to addition of TNF-a/ActD to the
medium.
If CO treatment was initiated after addition of TNF-a, less protection was
observed
(data not shown).
The Role of NF-KB in CO Protection
Whether CO-induced protection of hepatocytes depends upon NF-KB was
investigated. Figs. 4, 5, and 6A-6C present data illustrating that that CO
induced an
increase in NF-KB nuclear translocation and DNA binding in mouse hepatocytes
as
measured by NF-KB luciferase reporter assay activity, EMSA, and immunostaining
for
ReIA/p65 nuclear translocation, respectively.
To generate the data presented in Fig. 4, evaluation of NF-KB activation was
~5 performed using a luciferase reporter assay as described in Chow et al.
(J.Biol.Chem.
274: 10689-10692 (1999)). Briefly, hepatocytes were co-transfected with NF-KB
reporter constructs and
pIEP-Lac-z 24 hr prior to addition of BAY 11-7082 (10 ~M) or vehicle. Cells
were
incubated for 1 hr prior to CO (250 ppm). Luciferase activity (reported as
arbitrary
2o units; A.U.) was assayed 6 hr after exposure to CO or a cytokine mixture
(CM)
composed of TNF-a (500 U/ml), IL-1(3 (100 U/ml), and IFN-~ (100 U/ml), which
was
used as a positive control for NF-KB activation. Results were corrected for
transfection
efficiency and protein concentration.
To generate the data in Fig. 5, NF-KB DNA binding was evaluated using EMSA
25 in hepatocytes treated with CO (250 ppm). Note the time-dependent increase
in NF-KB
binding (total) with expression peaking at one hr (Lanes 1, 4, 7). Extracts
were then
supershifted to identify the different NF-KB dimers using antibodies against
p50 (Lanes
2, S, 8) and p65
(Lanes 3, 6, 9).
so To generate the data in Figs. 6A-6C, primary hepatocytes were immunostained
for nuclear p65 localization following exposure to 1 hr CO (250 ppm). Images
depict
nuclear translocation of NF-KB (arrows pointing to green nuclei that depict
the
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
translocation of NF-KB) in both CM (used as a positive control) and CO-treated
cells
versus no localization in air treated cells (arrows pointing to blue nuclei).
NF-KB luciferase reporter assay activity peaked one hour after placing cells
in
the CO atmosphere. A cytokine mixture (CM) was included in the treatment
groups as
a positive signal as well as a standard for maximum reporter activity by which
to
evaluate the effects of CO. Transfection efficiency in primary hepatocytes is
difficult,
but the reporter activity was very significant (*p<0.001 versus control).
These data
combined with the positive immunostaining and EMSA results support the notion
that
CO induces a moderate increase in NF-KB that in itself may in part result in
selective
gene expression. To evaluate whether NF-KB activity is needed for protection
mediated by CO, adenoviral gene transfer of IKBa was utilized to prevent NF-KB
translocation and BAY 11-7082 (1-IOmM, Calbiochem) was used to inhibit NF-KB
activation. The protective effects of CO were abrogated by inhibition of NF-KB
activation.
The Role of NF-KB-Dependent iNOS Expression in CO Protection
Whether CO-mediated protection of hepatocytes requires expression of iNOS
and generation of NO was investigated. The results are presented in Figs. 7,
8, and 9.
To generate the data in Fig. 7, evaluation of iNOS expression was performed
2o using a luciferase reporter assay as described in Lowenstein et al.
(Proc.Natl.Acad.Sci.U.S.A 90: 9730-9734 (1993)). Briefly, hepatocytes were co-
transfected with an iNOS promoter reporter construct and pIEP-LacZ 24 hr prior
to
exposure to BAY 11-7082 (10 p,M) or vehicle. Cells were incubated with BAY 1
hr
prior to exposure to CO (250 ppm). Luciferase activity (reported as arbitrary
units;
A.U.) was assayed as above. Cytokine mixture (CM; see above) was used as a
positive
control to induce iNOS expression, and results were corrected for transfection
efficiency and protein concentration.
To generate the data in Fig. 8, expression of iNOS protein was evaluated using
immunoblotting techniques. Briefly, cell extracts from hepatocytes were
treated with
3o TNF-a /ActD for 6-8 hr in the presence and absence of CO (250 ppm). Control
cells
received air or CO alone. Note in Fig. 8 that TNF-a induces iNOS expression
minimally, while those cells treated with TNF-a in the presence of CO show a
significantly greater induction in iNOS protein.
26
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
.. ..._ .. .. ..... ~,... .._.. ,..... . ..,.., ...." "..... a...~~ .....~~
To generate the data presented in Fig. 9, mouse hepatocytes were isolated from
inos ~ or from wild type C57BL/6J mice, which were then pre-treated for 1 hr
with L-
NIO (1 mM) to inhibit iNOS prior to CO administration. Those groups exposed to
CO
received a one-hour pretreatment prior to addition of TNF-a /ActD and were
then
returned to CO exposure. CO did not provide protection against cell death, as
evaluated via crystal violet exclusion 12 hr later, in cells where iNOS
expression was
absent or inhibited.
Exposure of hepatocytes to CO produced a highly significant increase in
activity in an iNOS luciferase reporter assay (Fig. 7). Again, a cytokine
mixture was
used as both a positive control in these low efficiency transfections and as a
standard by
which to evaluate the effects of CO. Consistent with the NF-KB dependence of
iNOS
expression, decreased reporter activity was observed in hepatocytes treated
with BAY
11-7082 (Fig. 7). Additionally, iNOS protein was markedly increased in
response to
TNF-a in the presence of CO compared to TNF-a alone (Fig. 8). Using
hepatocytes
~ 5 from iNOS knockout mice (inos-~ ) and wild type hepatocytes treated with
the selective
iNOS inhibitor L-NIO (1 mM, Calbiochem), applicants investigated whether CO
could
protect against TNF-a-induced death in the absence of iNOS activity.
Hepatocytes
lacking iNOS activity were not protected by CO from TNF-a -induced cell death
while
wild type hepatocytes were protected (Fig. 9). Taken together, these data show
that CO
2o requires NF-KB activation and iNOS expression to protect hepatocytes from
cell death
in vitro.
Inhaled CO is Protective Against Liver Failure
Whether inhaled CO protects mice against liver injury in a TNF-a /D-gal model
25 of fulminant hepatic failure was investigated. The results are presented in
Figs. 10 and
11A-11H.
To generate the data presented in Fig. 10, mice were pre-treated with CO (250
ppm) for one hour prior to receiving TNF-a /D-gal (0.3 pg/8 mg/mouse; i.p.,
respectively). After receiving TNF-a /D-gal, mice were returned to the CO
exposure
3o chamber and their serum was analyzed for ALT levels 6-8 hr later. Without
exposure
to CO, liver failure occurred in 6-8 hr driven primarily by apoptosis of
hepatocytes as
in the in vitro model described above. Serum ALT in mice treated with CO was
74%
lower than in air-exposed mice.
27
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
To generate the data presented in Figs. 11A-11H, liver samples from mice
treated with TNF-a /D-gal in the presence and absence of CO (250 ppm) for 8 hr
were
sectioned and stained for hematoxylin & eosin (H&E), activated caspase 3 (as
indicated
by an increase in red intensity), and for TUNEL positive cells (as demarcated
by the
increased green cellular staining; a marker of cell death). Nuclei stained
blue.
Exposure to CO markedly reduced TNF-a /D-gal-induced liver damage as assessed
by
H&E staining. Livers from mice exposed to CO also displayed fewer TUNEL
positive
cells, displayed less staining of activated caspase-3, and had normal
architecture. Air-
exposed control mice that received TNF-a /D-gal showed marked hepatic
inflammation, edema, hemorrhage and loss of architecture.
Results discussed above were confirmed using lipopolysaccharide (LPS, also
referred to as endotoxin) in place of TNF. In these confirmatory studies,
LPS/D-Gal
administration resulted in an increase in serum ALT levels from a control
level of 20
+/- 5 ILJ/ml to >1000 ILT/ml, as measured 8 hours following LPS/D-Gal
administration.
~ 5 In mice pretreated with 250 ppm CO, the increase in ALT was reduced by
>75%, to
250+/- 75 ILJ/ml. To further characterize the effects observed with CO in this
model,
serum interleukin-6 was measured, and found to be reduced 65% in animals
breathing
CO vs air-breathing controls (data not shown). Tissue histopathology of the
livers from
these mice was similar to that demonstrated using TNF/D-Gal. Untreated and CO-
2o treated mice (no LPS/D-Gal) had no signs of injury while those treated with
air and
LPS/D-Gal showed marked injury including edema, hemorrhage, neutrophil
infiltration
and an overall destruction of normal morphology and architecture. In contrast,
livers
from mice treated with CO and LPS/D-Gal were protected to the same extent as
mice
treated with CO and TNF/D-Gal. Few changes in the markers of inflammation
(edema,
25 hemorrhage, neutrophil infiltration) were observed. Architecture was
maintained and
appeared grossly similar to untreated and CO (in the absence of LPS/D-Gal)-
treated
mice. Overall, the use of LPS/D-Gal to induce acute hepatitis paralleled and
confirmed
data generated using TNF/D-Gal treatment.
28
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
The Role of iNOS in CO Protection Against Liver Damage
Whether hepatic iNOS protein levels were increased in the livers of CO-
exposed mice after treatment with TNF-a /D-gal was investigated using
immunoblotting techniques and immunohistochemistry. Further, whether CO would
protect inos ~ mice or wild type mice treated with the selective iNOS
inhibitor L-NIL
(10 mg/kg, i.p; dosed every 2 hours) was investigated to determine whether
iNOS
expression has a functional role. The results are provided in Figs. 12, 13A-
13D, and
14.
To generate the data presented in Fig. 12, male C57BL/6J mice were treated
with air or CO (250 ppm) 1 hr prior to TNF-a /D-gal (0.3 pg/8mg/mouse, i.p.,
respectively) administration. Six hours later, livers were harvested to
evaluate iNOS
expression by immunoblotting. Results show that iNOS expression was increased
modestly in air/ TNF-a/D-gal-treated mice, but was markedly increased in mice
treated
with TNF-a/D-gal and CO. As expected, inos-~ mice showed no expression of iNOS
protein.
To generate the data in Figs. 13A-13D, mouse liver sections were
immunostained for iNOS expression. The liver sections were obtained from mice
treated with TNF-a/D-gal in the presence or absence of CO, and from air and CO
controls that received no TNF-a/D-gal. Livers from mice exposed to CO and not
2o receiving TNF-a/D-gal displayed a modest increase in iNOS expression.
However, a
significantly greater increase in expression (indicated by an increase in
green-stained
cells) was observed in livers from mice that were exposed to CO and received
TNF-
a/D-gal. The increased expression appeared to be localized around blood
vessels.
To generate the data in Fig. 14, the efficacy of CO-induced protection was
tested in the absence of iNOS activity using inos ~ and wild type mice that
were treated
with L-NIL, the selective inhibitor of iNOS (L-NIL; 5 mg/kg, i.p. dosed every
two
hours). L-NIL was administered 2 hr prior to CO. CO-treated animals were then
pre-
treated (250 ppm) for 1 hr prior to TNF-a/D-gal. In the absence of iNOS
function/expression, CO is unable to protect against liver damage as assessed
by serum
3o ALT levels and histopathology (data not shown).
Thus, it appears the protective effect of inhaled CO in TNF-a-induced liver
failure is dependent upon iNOS activity.
29
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
The Role of HO-1 in CO Protection Against Acute Liver Failure
Whether CO and NO exert protection against acute liver failure through an HO-
1-dependent mechanism was investigated. The data are presented in Figs. 15,
16, 17,
and 18.
To generate the data presented in Fig. 15, immunoblotting was performed to
observe
HO-1 expression in the livers of mice that received TNF-a/D-gal in the
presence and
absence of CO (250 ppm). CO-treated mice showed a significant increase in HO-1
expression in both the presence and absence of TNF-a/D-gal.
To assess the role of iNOS on TNF-a/D-gal-induced HO-1 expression in the
liver (data presented in Fig. 16), mice were administered L-NIL (5 mg/kg,
i.p.) 2 hr
prior to pre-treatment with CO (250 ppm) and every 2 hr thereafter. Control
mice
received L-NIL and remained in room air. Note in Fig. 16 that CO increased HO-
1
expression in vehicle-treated mice, but was unable to induce expression when
iNOS
~ 5 was inhibited. L-NIL treatment alone had a minimal effect on HO-1
expression.
To test the protective role of CO-induced HO-1 (data presented in Fig. 17),
mice were given SnPP (50 ~tmol/kg, s.c.), the selective inhibitor of HO-1, 5
hr prior to
CO. Alternatively, the mice were given VPYRRO (VP), an NO donor (10 mg/kg,
s.c.).
VP was selectively designed to deliver NO directly to the liver. One hour
after the
2o initial VP dose, the animals were exposed to CO for 1 hr prior to
administration of
TNF-a/D-gal (see above). Serum ALT levels were determined 6-8 hr later. Note
that
CO was not able to provide protection in animals where HO-1 activity was
blocked.
VP, when administered 2 hr prior and then every 2 hr thereafter, provided
protection
against injury as determined 8 hour later by serum ALT measurements.
25 To generate the data presented in Fig. 18, wild type C57BL/6J mice were
pretreated for 24 hr with L-NIL in the drinking water (4.5 mM) as described in
Stenger
et al. (J. Exp. Med. 183: 1501-1514 (1996)). These mice and inos-~-omice were
then
administered CoPP. L-NIL was maintained in the water throughout the
experiment.
Control and inos ~ mice received normal drinking water. Twenty-four hr after
3o administration of CoPP, TNF-a/D-gal was administered and serum ALT
determined 6-
8 hr later. Note in Fig. 18 that induction of HO-1 provides protection
regardless of the
presence of iNOS.
Immunoblotting of liver extracts from mice treated with CO in the presence
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
or absence of TNF-a/D-gal showed up-regulation of HO-1 (Fig. 15). The addition
of
the
iNOS inhibitor L-NIL to these above groups, which abrogated the protection
(Fig. 17),
also prevented up-regulation of HO-1 (Fig. 16). To determine whether HO-1 was
central to CO-elicited hepatoprotection, tin protoporphyrin-IX (SnPP, 50
pmol/kg, s.c.,
Frontier Scientific) was used as a selective inhibitor of HO-1 activity. SnPP
significantly diminished the protective effects of CO in this model (Fig. 17).
SnPP
administration in the absence of TNF-a/D-gal had no deleterious or protective
effects
(data not shown). These results suggest that up-regulation of HO-1 is
important to the
protective effects of CO.
To determine if up-regulation of HO-1 would also be needed if protection was
initiated by NO, mice were treated with the pharmacological NO donor V-
PYRRO/NO.
This agent is metabolized by the liver, resulting in release of NO by
hepatocytes. V-
PYRRO/NO also provides protection following LPS/D-gal or TNF-a/D-gal
~ 5 administration. Mice were randomized and treated with TNF-a/D-gal with or
without
SnPP to evaluate the role of HO-1. V-PYYRO/NO was protective, as assayed by
senim ALT. However, SnPP abrogated the ability of this NO donor to protect
against
liver damage (Fig. 17). Thus, it appears that CO- or NO-initiated
hepatoprotection is at
least partially dependent on HO-1.
2o Because these data suggest that CO and NO require HO-1 activity to protect
against TNF-a-induced hepatocyte death, whether protection mediated by HO-1
requires iNOS activity was investigated. Using inos-~ mice, HO-1 was induced
via
administration of CoPP. TNF-a/D-gal was injected 24 hr thereafter, at the peak
of HO-
1 expression, and liver damage was assessed 6-8 hr later. The results show
that
25 induction of HO-1 was able to significantly prevent liver injury
independently of iNOS
activity with a >50% reduction in serum ALT (Fig. 18). These results were
confirmed
using L-NIL. Mice were pre-treated with drinking water containing L-NIL (4.5
mM)
for 24 hours. This method effectively inhibits NOS activity. Control mice
received
normal water. Subsequently, CoPP was administered to induce HO-1 expression
and
30 24 hours thereafter mice were challenged with TNF-a/D-gal. L-NIL treatment
alone
did not change the severity of injury induced in this model. All animals
receiving
CoPP (with and without L-NIL) were protected from liver injury (Fig. 18).
31
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
Whether HO-1 expression is required for CO- or NO-induced protection from
TNF-a/ActD-induced hepatocyte cell death was investigated. The data are
presented in
Figs. 19 and 20.
To generate the data presented in Fig. 19, mouse hepatocytes were isolated
from
HO-1 null mice (hmox-I-~) and wild type (C57BL/6J) littermates, pretreated for
1 hour
with CO
(250 ppm), and treated with TNF-a/ActD. Viability was assayed as described
above.
CO significantly protected wild type hepatocytes, but was unable to protect
hepatocytes
isolated from hmox-I-l mice.
To generate the data presented in Fig. 20, mouse hepatocytes were isolated
from
HO-1 null mice (hmox-1-~) and wild type (C57BL/6J) littermates, pretreated
with the
NO donor SNAP (S00 pM), and then treated with TNF-a/ActD 1 hour later. SNAP
has
been demonstrated to protect hepatocytes in this model. SNAP significantly
protected
against cell death in wild type hepatocytes but did not provide significant
protection
against cell death in hepatocytes isolated from hrnox-~-~ mice.
As discussed above, air-treated wild type and hmox-I-~ cells exposed to TNF-
a/ActD underwent cell death as expected, while CO- or NO- treated wild type
cells
were protected in the presence of TNF-a/ActD (Figs. 19 and 20). The protection
conferred by CO and NO was lost in cells lacking functional HO-1 (hmox-1-~).
Thus,
2o it appears that HO-1 can provide protection in this model without the
involvement of
iNOS, suggesting that HO-1 or one or more of its catalytic products can, in
part, exert
cytoprotective effects in this model.
Inhaled CO is Protective Against Acetaminophen-lnduced Hepatitis
Whether inhaled CO is protective against acetaminophen (APAP)-induced
hepatitis was investigated. The data are presented in Fig. 21.
To generate the data in Fig. 21, Male C57BL/6J mice were exposed to CO (250
ppm) either 1 hr prior or 4 hr post administration of APAP (500 mg/kg, i.p.).
The mice
were then maintained in CO for the duration of the experiment. Serum ALT
levels
3o were determined 20 hr after APAP administration. Control mice received APAP
and
were maintained in air. This protocol was designed to allow hepatitis to
develop for
four hours before administering CO. CO significantly reduced damage to the
liver as
assessed by serum ALT (622 t 44 vs 175 t 137, p < 0.01 as compared to
controls).
32
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
This protection was similar to that observed in a separate group of animals
that had
been pre-treated with CO prior to APAP. These data support the therapeutic use
of CO
in a clinically relevant situation where treatment would begin after the
initiation of
hepatitis.
The results discussed in this Example demonstrate that a low concentration of
CO can protect against TNF-a/D-gal-induced fulminant hepatitis and illustrate
a unique
and previously unrecognized dependence on both HO-1 and iNOS in the CO-induced
protection of livers from damage by TNF-a/D-gal.
Without intending to be bound by theory, it is possible that CO mediated
protection operates by activating NF-KB, which in the presence of an
inflammatory
stimulus leads to the up-regulation of iNOS with the consequent production of
NO. In
addition to the induction of iNOS, other NF-KB dependent
antiapoptotic/protective
genes may be induced. During the
~ 5 1 hour pre-treatment with CO and before the cells are treated with TNF-a,
significant
activation of NF-KB was present, which could be part of the priming of the
cellular
apparatus discussed above. The activation of NF-rcB by CO may in part result
from a
mild increase in reactive oxygen species generation originating from the
mitochondria
(preliminary observations). One hour might also permit time for expression of
NF-~cB -
2o dependent anti-apoptotic genes. The next step in such a hypothetical model
might lead
to NO production following the up-regulation of iNOS. NO leads to up-
regulation of
HO-l, the activity of which confers protective effects. The protective effect
of HO-1
could be due to removal of heme or to any one or more of its three products:
CO,
biliverdin/bilirubin or iron/ferritin. Given that exogenous CO was
administered
25 throughout the duration of the experiments, it appears unlikely that
endogenously-
produced CO alone mediates HO-1 protection. However, the combination of CO
with
other products of HO-1 or these other products acting individually might be
involved.
In a study described above, CO was administered in a clinically-relevant model
of acetaminophen (APAP)-induced hepatitis that has a time course that is
similar to the
3o development of acute hepatitis in humans. The data demonstrate that
exposure to CO 4
hours after administration of APAP (SOOmg/kg, i.p.) resulted in a 62%
reduction in
liver injury
(Fig. 2I). In this model of APAP-induced liver injury, mice show signs of
hepatitis as
33
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
early as
2-4 hours after APAP administration and lethality occurs by 24-48 hours. Thus,
CO
was administered after the initiation of liver injury. Consistent with the
data in the
APAP model are the results in a murine model of hemorrhagic shock where the
therapeutic initiation of inhaled CO during resuscitation following a 2.5 hour
shock
phase resulted in protection against liver injury (>65% reduction in serum ALT
at 24 hr
p<0.01; n=6-10/group).
In summary, employing a model of liver injury driven principally by TNF-a-
induced apoptosis, the following was demonstrated: first, inhaled CO can
prevent
hepatitis in this model; second, protection by CO requires generation of a
second
gaseous molecule, NO; third, NO exerts its beneficial effects, at least in
part, via
upregulation of HO-1; and fourth, up-regulation of HO-1 is protective without
a need
for iNOS/NO activity, i.e., without an obligate continuation of the cycle.
Example 2. Protocol for the Treatment of Hepatitis
The following example illustrates protocols for use in treating a patient
diagnosed as suffering from hepatitis. The example also illustrates protocols
for
treating patients before, during, and/or after surgical procedures, e.g., a
surgical
procedure to transplant a liver. Skilled practitioners will appreciate that
any protocol
2o described herein can be adapted based on a patient's individual needs, and
can be
adapted to be used in conjunction with any other treatment for hepatitis.
Treatment of Patients
Treatment of a patient with CO can begin on the day the patient is diagnosed
as
suffering from hepatitis, for example, hepatitis caused by viral infection
and/or alcohol
abuse. The patient can be diagnosed by a physician using any art-known method.
For
example, a physician may make such a diagnosis using data obtained from blood
tests,
e.g., tests to determine serum ALT levels and tests to determine whether a
patient is
infected with a particular virus (e.g., any known hepatitis virus). Further, a
physician
3o may consider a patient's medical history in making such a diagnosis (e.g.,
by
considering whether a patient is an alcoholic or a chronic drug user). The
patient can
inhale CO at concentration of about 250 to 500 ppm for one hour per day. This
treatment can continue for about 30 days, or until the patient is diagnosed as
no longer
34
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
having or being at risk for hepatitis.
Liver Transplant Procedures
Treatment of a Liver Donor
Prior to harvesting a liver or portion thereof, the donor can be treated with
inhaled carbon monoxide (250 ppm) for one hour. Treatment can be administered
at
doses varying from 10 ppm to 1000 ppm for times varying from one hour to six
hours,
or for the entire period from the moment when it becomes possible to treat a
brain-
dead (cadaver) donor to the time the organ is removed. For a human donor,
treatment
should start as soon as possible following the declaration that brain death is
present. In
some applications, it may be desirable to begin treatment before brain death.
For non-human animals (e.g., pigs) to be used as xenotransplantation donors,
the live donor animal can be treated with relatively high levels of inhaled
carbon
monoxide, as desired, so long as the carboxyhemoglobin so produced does not
compromise the viability and function of the organ to be transplanted. For
example,
one could use levels greater than 500 ppm (e.g., 1000 ppm or higher, and up to
10,000
ppm, particularly for brief times).
Treatment of the Liver in situ
2o Before a liver is harvested from a donor, it can be flushed or perfused
with a
solution, e.g., a buffer or medium, while it is still in the donor. The intent
is to flush
the liver with a solution saturated with carbon monoxide and maintained in a
carbon
monoxide atmosphere so that the carbon monoxide content remains at saturation.
Flushing can take place for a time period of at least 10 minutes, e.g., 1
hour, several
25 hours, or longer. The solution should ideally deliver the highest
concentration of
carbon monoxide possible to the cells of the liver (or portion thereof).
Treatment of the Liver ex vivo
A liver can be preserved in a medium that includes carbon monoxide from the
3o time it is removed from the donor to the time it is transplanted to the
recipient. This
can be performed by maintaining the liver in the medium comprising CO, or by
perfusing it with such a medium. Since this occurs ex vivo rather than in an
animal,
very high concentrations of CO gas can be used (e.g., 10,000 ppm) to keep the
medium
CA 02485465 2004-11-09
WO 03/096977 PCT/US03/15263
saturated with CO.
Treatment of a Liver Recipient
Treatment of the recipient with CO can begin on the day of transplantation at
least
30 minutes before surgery begins. Alternatively, it could begin at least 30
minutes
before re-perfusion of the organ in the recipient. It can be continued for at
least 30
minutes, e.g., 1 hour. Carbon monoxide doses between 10 ppm and 3000 ppm can
be
delivered for varying times, e.g., minutes or hours, and can be administered
on the day
of and on days following transplantation. For example, the patient can inhale
a
concentration of carbon monoxide, e.g., 3000 ppm, for three consecutive 10
second
breath holds. Alternatively, a lower concentration of the gas can be delivered
intermittently or constantly, for a longer period of time, with regular
breathing rather
than breath holding. Carboxyhemoglobin concentrations can be utilized as a
guide for
appropriate administration of carbon monoxide to a patient. Usually,
treatments for
recipients should not raise carboxyhemoglobin levels above those considered to
pose an
acceptable risk for a patient in need of a transplant.
A number of embodiments of the invention have been described. Nevertheless,
it will be understood that various modifications may be made without departing
from
the spirit and scope of the invention. Accordingly, other embodiments are
within the
2o scope of the following claims.
36
